Table 2.
Intervention effect of azithromycin treatment compared to placebo.
| Biomarker (Log10) | 48-week β ± SE | p Value | FDR Adjusted p Value | 72-week β ± SE | p Value | FDR Adjusted p Value |
|---|---|---|---|---|---|---|
| MMP-1 | −0·07 ± 0·03 | 0·016 | – | −0·04 ± 0·031 | – | – |
| MMP-10 | −0·09 ± 0·03 | 0·001 | 0·014 | −0·01 ± 0·031 | – | – |
| MMP-12 | −0·07 ± 0·03 | 0·023 | – | −0·04 ± 0·04 | – | – |
| sCD14 | −0·01 ± -0·01 | 0.488 | – | −0·03 ± 0·01 | 0·022 | – |
| sCD163 | 0·02 ± 0·02 | – | – | 0·06 ± 0·02 | 0·008 | – |
| CRP | −0·37 ± 0·11 | 0·001 | 0·014 | −0·15 ± 0·12 | – | – |
| E-Selectin | −0·05 ± 0·02 | 0·002 | 0·02 | −0·02 ± 0·02 | – | – |
| Fas | 0·03 ± 0·01 | 0·016 | – | −0·004 ± 0·01 | – | – |
| GCSF | −0·04 ± 0·02 | 0·019 | – | −0·04 ± 0·02 | 0·03 | – |
| PC 1 | −0·56 ± 0·23 | 0·014 | – | −0·42 ± 0·25 | – | – |
| PC 3 | −0·32 ± 0·11 | 0·003 | 0·022 | −0·12 ± 0·12 | – | – |
| PC 4 | 0·37 ± 0·11 | 0·001 | 0·014 | 0·02 ± 0·13 | – | – |
| PC 7 | −0·18 ± 0·08 | 0·022 | – | −0·13 ± 0·09 | – | – |
Intervention effect on biomarkers (log10) and principal components (PC). Coefficients (β) represent interaction between trial arm and time at 48 weeks and 24 weeks post treatment cessation (72 weeks). HIV-1 suppression, age, sex, and indication of previous treatment for TB are included as covariates. P values represent significance of biomarker and dummy-time value interaction term in mixed effect model. FDR adjusted p-value calculated using Benjamini-Hochberg method. Only biomarkers with p < 0·05 at any timepoint shown. Blank cells are non-significant (p > 0.05). SE = Standard Error.